Novavax top investor ends proxy fight after Sanofi deal
Shah Capital, a top shareholder of Novavax (NASDAQ:NVAX), has withdrawn its proxy campaign against the company days after the COVID-19 vaccine maker struck a licensing agreement with French pharma giant Sanofi (SNY).